SME
IPO ·
NSE SME
Avience Biomedicals Ltd
Listed
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Issue details
Price band
₹196 – ₹208
Face value
₹10
Lot size
600 shares
Minimum investment
₹2,49,600
Issue size
₹30.24 Cr
Fresh issue
₹28.53 Cr
Offer for sale
—
Issue type
Book Built
Exchange
NSE SME
Key dates
Opens
18 Jun 2026
Closes
22 Jun 2026
UPI mandate cut-off
5:00 PM on 22 Jun 2026
Allotment
23 Jun 2026
Refunds
24 Jun 2026
Shares in demat
24 Jun 2026
Listing
25 Jun 2026
Subscription and listing
Subscription
267.95x
Listing price
₹395.20
Registrar
Skyline Financial Services Pvt Ltd
Lead manager
Fintellectual Corporate Advisors
Subscription by category
Total
267.95x
Total applications
1,90,169
Anchor investors
Amount raised
₹8.52 Cr
Bid date
17 Jun 2026
50% lock-in ends
23 Jul 2026
Rest lock-in ends
21 Sep 2026
Listing day
Issue price
₹208
Open
₹395.20
High
₹414.95
Low
₹395.20
Day close
₹414.95
Listing gain at open
+90.00%
Issue structure
Shares reserved per category and share of the total issue
QIB Shares Offered
6,83,400
47.01%
Anchor Investor Shares Offered
4,09,800
28.19%
QIB (Ex. Anchor) Shares Offered
2,73,600
18.82%
NII Shares Offered
2,07,000
14.24%
bNII > ₹10L
1,38,000
9.49%
sNII < ₹10L
69,000
4.75%
Retail Shares Offered
4,81,200
33.10%
Market Maker Shares Offered
82,200
5.65%
Total Shares Offered
14,53,800
100.00%
Finaccle’s quick read
Apply
FY25 income up 89%, PAT up 238%, ROE 22.38%, D/E 0.94, post-issue P/E 16.56x.
A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.
About the company
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
Founded
Promoters
Promoter holding
Financial performance
Period
PAT
ROE
22.38%
ROCE
16.99%
Debt / equity
0.94
PAT margin
—
P/E post issue
16.56
Market cap
₹114.09 Cr
Use of IPO money
Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Y
₹14.05 Cr
Funding the working capital requirements of the Company
₹8.25 Cr
General Corporate Purposes
₹3.97 Cr
Public Issue Expenses
₹3.97 Cr
Strengths
✓
Revenue up 89% in FY25 to ₹45.97 Cr
✓
PAT up 238% in FY25 to ₹7.23 Cr
✓
ROE of 22.38% and ROCE of 16.99%
✓
Moderate leverage: debt to equity 0.94
Risks to watch
!
SME platform: large lot size and thinner trading liquidity
Planning to take your own company public?
Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.
Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.
Last updated:
Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.